Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata referenced "BIOLIFE SOLUTIONS INC," but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Three months ended March 30, 1997.
Business Overview: The Company researches, develops, manufactures, and markets cryosurgical systems, primarily the "AccuProbe" line, for use in dermatology, surgery, and urology. In March 1997, the Company received FDA clearance for the AccuProbe 600 series and submitted an application for the Cryo-lite(R) hand-held products.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Revenue | $986,849 | $2,026,593 |
| Gross Profit | $642,357 | $1,012,490 |
| Gross Margin | 65% | 50% |
| Operating Loss | $(106,272) | $(416,465) |
| Net Loss | $(90,299) | $(412,668) |
| Cash and Equivalents (End of Period) | $1,474,496 | $1,265,757 |
| Working Capital | $3,047,057 | N/A |
| Net Cash Used in Operating Activities | $(240,608) | $(1,367,787) |
Liquidity: As of March 30, 1997, total cash, cash equivalents, and short-term investments were $1,584,646. The Company reported an accumulated deficit of $26,585,043.
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 51% to $986,849 from $2,026,593. This was driven by a drop in AccuProbe system sales (1 unit sold in Q1 1997 vs. 7 in Q1 1996) and fewer procedures performed using disposable accessories.
- Expense Reductions: Despite lower revenue, operating expenses decreased significantly due to headcount reductions:
- Research and Development: Decreased 12% to $275,780.
- Sales and Marketing: Decreased 66% to $203,151.
- General and Administrative: Decreased 48% to $269,698.
- Improved Margins: Gross margin improved to 65% from 50% due to reduced field service expenses and a favorable product mix.
- Reduced Net Loss: Net loss narrowed to $90,299 from $412,668 in the prior year period.
Outlook, Risks, and Contingencies
Management Commentary & Outlook:
- Management expects sales for the remainder of 1997 to be lower than comparable prior-year periods.
- Current cash and working capital are deemed sufficient to fund operations for the next 12 months, though the Company may pursue short-term financing or additional equity if necessary.
- Capital expenditures for the year are expected to remain under $750,000.
Key Risks:
- Reimbursement Uncertainty: Sales are heavily constrained by the lack of formal Medicare reimbursement for urologic cryosurgery. The Health Care Financing Administration (HCFA) is considering a national non-coverage policy pending a clinical study.
- Legal Proceedings: The Company is involved in litigation against EndoCare, Inc. and former employee Dr. ZhoaHua Chang, alleging misappropriation of trade secrets and breach of contract. A hearing on a preliminary injunction is scheduled for July 2, 1997. Dr. Chang has filed a counter-suit.
Investor Verification Checklist
- Verify the status of the HCFA clinical study and potential impact on Medicare reimbursement for urologic cryosurgery.
- Monitor the outcome of the litigation against EndoCare, Inc. and Dr. Chang, including the July 2, 1997 injunction hearing.
- Assess the timeline for FDA approval of the Cryo-lite(R) hand-held products and their potential contribution to revenue.
- Review the Company's ability to maintain liquidity if sales remain below historical levels, specifically regarding the need for additional equity financing.